‘Outstanding Issues’ Near For Products Approaching EU Review End – Including Neulasta Biosimilar
Executive Summary
Ammtek, Pfizer, Portola and Roche are among the companies that are likely to find out what remaining concerns the European Medicines Agency’s key advisory panel, the CHMP, has regarding products of theirs that are nearing the end of the review pathway. Questions are likely to be in store for the sponsor of a biosimilar version of pegfilgrastim.
You may also be interested in...
EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic
EU regulators meeting in London are finalizing the outstanding questions they have for companies whose products are approaching the final stages of the approval process.
EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic
EU regulators meeting in London are finalizing the outstanding questions they have for companies whose products are approaching the final stages of the approval process.